SOPHiA GENETICS SA·4

Apr 3, 6:59 AM ET

Muken Ross 4

4 · SOPHiA GENETICS SA · Filed Apr 3, 2026

Research Summary

AI-generated summary of this filing

Updated

SOPHiA GENETICS (SOPH) President Muken Ross Receives Award

What Happened
Muken Ross, President of SOPHiA GENETICS SA (SOPH), received equity awards on April 2, 2026: 431,211 restricted stock units (RSUs) and 628,743 derivative awards (share options), for a total of 1,059,954 share-equivalents. Both grants were reported at $0.00 (no cash paid at grant); these are compensation awards, not open-market purchases or sales.

Key Details

  • Transaction date: 2026-04-02; Form 4 filed 2026-04-03 (next day).
  • Grant amounts/prices: 431,211 RSUs @ $0.00; 628,743 derivative awards @ $0.00. Total = 1,059,954.
  • Shares owned after transaction: Not disclosed in the filing.
  • Vesting notes (from filing):
    • RSUs: 25% vest on April 2, 2027; remaining 75% vest in equal quarterly installments through April 2, 2030. (F1)
    • Options: 25% vests on April 2, 2027; remaining vest in equal monthly installments through April 2, 2030. (F2)
  • Timeliness: Filing appears timely (filed the day after the grant); no late filing indicated.

Context
These are compensation grants (RSUs and options) that convert to actual shares only as they vest; they do not represent an immediate purchase or sale. Derivative awards (options) give the holder a future right tied to vesting; exercise (and any subsequent sale) would be reported separately. Such grants are common executive compensation and, by themselves, are not a direct market signal.

Insider Transaction Report

Form 4
Period: 2026-04-02
Muken Ross
DirectorChief Executive Officer
Transactions
  • Award

    Ordinary Shares

    [F1]
    2026-04-02+431,211431,211 total
  • Award

    Share Option (Right to Buy)

    [F2]
    2026-04-02+628,743628,743 total
    Exercise: $5.04Exp: 2036-04-02Ordinary Shares (628,743 underlying)
Footnotes (2)
  • [F1]Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
  • [F2]The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken|2026-04-03

Documents

1 file
  • 4
    wk-form4_1775213969.xmlPrimary

    FORM 4